Original Article
Title:Mepolizumab decreases tissue eosinophils while increasing type-2
cytokines in eosinophilic chronic rhinosinusitis
Short title: Tissue effect of mepolizumab in chronic
rhinosinusitis
Sophie Walter, BMed MD BSc(Med)Hons1; Jacqueline Ho,
MD1, 2; Raquel Alvarado, PhD1; Greg
Smith, PhD3, David R. Croucher, PhD2,
5; Sharron Liang, MD6; Simone L. Van Es,
MD3, 4; Peter Earls, MD1, 6; Janet
Rimmer, MD MBBS1, 7, 8; Raewyn Campbell,
MD1, 9, 10; Larry Kalish, MBBS MS MMed (Clin Epi)1, 11, 12; Raymond Sacks, MBBCh1,
10-12; Richard J. Harvey, MD PhD1, 10
- Rhinology and Skull Base Research Group, St Vincent’s Centre for
Applied Medical Research, University of New South Wales, Sydney,
Australia
- St Vincent’s Clinical School, Faculty of Medicine, University of New
South Wales, Sydney, Australia
- School of Medical Sciences, University of New South Wales, Sydney,
Australia
- New South Wales Health Education and Training Institute, Sydney,
Australia
- Garvan Institute of Medical Research, Sydney, NSW 2010, Australia.
- Department of Anatomical Pathology, St Vincent’s Hospital, Sydney,
Australia
- Woolcock Institute, University of Sydney, Sydney, Australia
- Faculty of Medicine, Notre Dame University, Sydney, Australia
- Department of Otolaryngology Head and Neck Surgery, Royal Prince
Alfred Hospital, Sydney, Australia
- Faculty of Medicine and Health Sciences, Macquarie University, Sydney,
Australia
- Department of Otolaryngology, Head and Neck Surgery, Concord General
Hospital, University of Sydney, Sydney, Australia
- Faculty of Medicine, University of Sydney, Sydney, Australia
Corresponding author: Sophie Walter; address: 67 Burton Street,
Darlinghurst, New South Wales, 2010, Australia; Tel: +614 9360 4811;
Fax: +614 9360 9919; Email:
sophie.walter20@gmail.com